Prevacid, Nexium DTC Ads Target Former Vioxx Patients
Proton pump inhibitor marketers are using direct-to-consumer print ads to target patients coming off Merck's COX-2 inhibitor Vioxx by highlighting PPIs' efficacy in reducing NSAID-related ulcers
You may also be interested in...
Pfizer's COX-2 inhibitor Celebrex can remain on the market with new labeling warnings, including a "black box" about the increased risk of cardiovascular events, an FDA advisory committee recommended Feb. 18
TAP's Prevacid NapraPAC is among the early winners in the arthritis market following the withdrawal of Merck's Vioxx, IMS Health data suggest
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011